Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farletuzumab in platinum-sensitive relapsed ovarian cancer
NCT00849667Phase 3Terminated
- Sponsor
- Morphotek
- Start
- Apr 2009
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial of farletuzumab in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by Morphotek. Primary endpoint: Progression-free Survival at 44 months. Started Apr 2009; status: terminated.
02
Drugs
farletuzumab
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00849667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00849667.